Richmond Pharmacology presents further QT insulin data next month in San Diego!

Posted:
30
August 2012

30th August 2012

Richmond Pharmacology presents further QT insulin data next month in San Diego!

We welcome you to attend the 2012 Annual Meeting of the American College of Clinical Pharmacology (ACCP), taking place 23rd-25th September, at the Sheraton San Diego Hotel & Marina.This topic of this year's meeting is  Translating Clinical Pharmacology Research into Optimized Patient Care  and will encompass a series of Pre-meeting Workshops and Symposia on related content such as the role of clinical pharmacology in speeding the development of new anti-infective drugs to combat drug resistance, pharmacometrics in hospital-based pharmacotherapy, innovations in drug therapies, and much more.Join Richmond Pharmacology on Day 1, Sun 23rd Sep between 6 and 8pm, where we will present further data on studies using techniques such as the euglycaemic insulin clamp to probe the effect of insulin on the QT interval in healthy Caucasian and Japanese volunteers:

  • Late changes after a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects
  • The impact of insulin levels on QTc interval in Thorough QT studies conducted in healthy subjects

View full program

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more